Oral Immunotherapy in Young Children With Food Allergy

Food Allergy Clinical Trial

— ORKA-NL  

Official title:

A Randomized Controlled Trial to Investigate the (Cost)Effectiveness of Oral Immunotherapy With Different Allergens in Young Children With an Established Food Allergy

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05738798
• Other study ID #: NL81774.075.22
• Status: Enrolling by invitation
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: July 1, 2025

Study information

• Verified date: February 2023
• Source: Deventer Ziekenhuis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about oral immunotherapy in food allergic children < 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.

Description:

Primary objective: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction in children under the age of 30 months with an established food allergy compared to routine care? Secondary objective: What is the effect of early low-dose oral immunotherapy in children under the age of 30 months with an established food allergy on (allergy specific) quality of life of parents and children compared to routine care? Study design: randomized controlled superiority trial Study population: Children between 9 and 30 months old with an IgE-mediated food allergy to peanut, tree nuts, cow's milk and/or hen's egg as proven by an oral food challenge. Intervention: 1-year low-dose oral immunotherapy (daily 300 mg allergenic protein) compared to strict avoidance in the control group. Main study parameters/endpoints: Long-term tolerance as assessed by an exit oral food challenge at 4 weeks after discontinuation of the oral immunotherapy, combined with uncomplicated consumption of a full dose of the specific food at 6 months after discontinuation of the therapy.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 500
• Est. completion date: July 1, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Months to 30 Months

Eligibility

Inclusion Criteria:

• An IgE-mediated food allergy to peanut, cashew, hazelnut, walnut, cow's milk and/or hen's egg as proven by sensitization to the specific allergen (sIgE > 0.35kU/l) and a positive oral food challenge.
• The fore-mentioned allergens are introduced into the diet of the child (the child is tolerant for the specific allergen(s)), or the child is diagnosed with a food allergy for the specific allergen(s).

Exclusion Criteria:

• (Suspected) eosinophilic oesophagitis
• Uncontrolled asthma/ viral wheeze.
• The inability of parents to follow instructions, recognize allergic reactions or administer emergency medication.
• Participation in any other intervention study at the time of the OIT study, with the exception of studies on guided early introduction of highly allergenic foods.

Related Conditions & MeSH terms

• Food Allergy
• Food Hypersensitivity
• Hypersensitivity

Intervention

Dietary Supplement:
• oral immunotherapy
oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.

Locations

Country	Name	City	State
Netherlands	Amsterdam UMC, location AMC	Amsterdam
Netherlands	Reinier de Graaf Gasthuis	Delft
Netherlands	Deventer hospital	Deventer	Overijssel
Netherlands	Martini hospital	Groningen

Sponsors (4)

Lead Sponsor	Collaborator
Deventer Ziekenhuis	Dutch National Health Care Institute, University of Twente, Utrecht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with sustained unresponsiveness to consumption of a specific allergenic food 4 weeks after stopping the 1-year oral immunotherapy (OIT)	Definition of sustained unresponsiveness: a participant who passed an oral food challenge (OFC) to 4.2 gram of the allergenic protein.; Definition of the allergenic protein: the allergenic protein which induced an allergic response at an OFC at the start of the study, and was administered to the patient during the OIT (i.e. milk, egg, peanut, hazelnut, cashew or walnut).	Timing of the OFC: week 57 (52 weeks of OIT, followed by a 4-week allergenic food-free interval)
Primary	Percentage of tolerant participants at week 78	In children achieving sustained unresponsiveness (outcome 1), the allergen is introduced into the diet by parents at a regular base. Six months after discontinuation of the OIT, tolerance to the specific allergenic protein is assessed.; Definition of tolerant: Percentage of children with uncomplicated (i.e. without any allergic symptoms) consumption at home of a full dose of the specific allergenic protein (e.g. a glass of milk or a sandwich with peanut butter).	week 78 = 6 months after stop of the 1-year oral immunotherapy
Primary	Cost-effectiveness ratio at 18 months (week 78).	Incremental cost-effectiveness ratio (ICER) at 18 months (week 78). Costs associated with oral immunotherapy will be measured in Euros. Effectiveness will be considered as percentage of tolerant participants at week 78.	18 months (week 78).
Primary	Cost-utility ratio at 18 months (week 78).	Incremental cost-utility ratio (ICUR) will be calculated for both groups using health-related quality of life (HRQoL) scores from the AQoL-6D (assessment of quality of life - 6 dimensions) and converted to utility scores and will be expressed in euros per QALY.	18 months (week 78): at the end of the study period.
Secondary	Health related quality of life of children, during the 1-year OIT and six months after the therapy (week 78)	Children's quality of life as measured by: - Food Allergy Quality of Life Questionnaire - parental form (FAQLQ-PF) This questionnaire consists of 14 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no impact of food allergy on quality of life), maximum score is 84 (high impact of food allergy on quality of life)	during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)
Secondary	Occurrence of Adverse Event(s) Related to Oral Immunotherapy up to 65 weeks study participation	(Serious) adverse events related to oral immunotherapy	during build-up (up to 3 months) and 1-year oral immunotherapy, total 65 weeks
Secondary	Levels of allergy-related immune parameters	Levels of allergen specific IgE and IgG4	at start of the therapy and after 6 and 12 months maintenance therapy
Secondary	adherence	Rate of daily providing the oral immunotherapy	during 1 year oral immunotherapy
Secondary	Health related quality of life of parents, during the 1-year OIT and six months after the therapy (week 78)	Parental quality of life as measured by: - Food Allergy Quality of Life- Parental Burden (FAQL-PB) This questionnaire consists of 17 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no parental burden), maximum score is 102 (severe parental burden)	during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)